Thyroid-like cholangiocarcinoma is a very uncommon variant of peripheral-type cholangiocarcinoma. To date, only 4 prior cases have been reported. The molecular features of this tumor have not been described. We report a case of a 60-year-old woman with a tumor that evolved over a period of 10 years. A left hepatectomy specimen showed an 11 cm tumor that on histology exhibited areas reminiscent of a thyroid tumor with follicular and insular features which were positive on immunohistochemistry for cytokeratin 7 and in-situ hybridization for albumin. A detailed molecular analysis failed to show mutations common to cholangiocarcinomas but revealed frameshift mutations in 2 chromatin-remodeling genes, CREBBP and KMNT2A. This case confirms that thyroid-like cholangiocarcinoma is a histologic variant of this tumor that is associated with relatively low growth. As most cholangiocarcinomas, it is diffusely positive for cytokeratin 7 and albumin by in-situ hybridization. Given its rarity, the molecular alterations in this specific histologic subtype remain to be fully elucidated.
SahaSKParachoniakCAGhantaKS, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513(7516):110-114.
4.
CarpizoDRD’AngelicaM. Management and extent of resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am.2009;18(2):289-305.
5.
AishimaSOdaY. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci.2015;22(2):94-100.
6.
KimYMorisDPZhangXF, et al. Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis. J Surg Oncol. 2017;116(6):643-650.
7.
FongYBlumgartLHLinEFortnerJGBrennanMF. Outcome of treatment for distal bile duct cancer. Br J Surg. 1996;83(12):1712-1715.
8.
WHO Classification of Tumours Editorial Board, ed. Who Classification of Tumours of the Digestive System. Fifth Edit. International Agency for Research on Cancer; 2019.
9.
ChenSHZhengZYWangHL, et al. Thyroid-like intrahepatic cholangiocarcinoma: report of a case and review of the literature. Int J Surg Pathol.2018;26(7):649-654.
10.
Chablé-MonteroFAmy ShahBSde OcaDMMÁngeles-ÁngelesAHensonDEAlbores-SaavedraJ. Thyroid-like cholangiocarcinoma of the liver: an unusual morphologic variant with follicular, trabecular and insular patterns. Ann Hepatol.2012;11(6):961-965.
11.
FornelliABondiAJovineEEusebiV. Intrahepatic cholangiocarcinoma resembling a thyroid follicular neoplasm. Virchows Arch.2010;456(3):339-342.
12.
MittalNBalMRamadwarMet al. Pathologic Doppelganger: thyroid-like intrahepatic cholangiocarcinoma with synchronous primary thyroid carcinoma in a young woman. Ann Hepatobiliary Pancreat Surg. 2020;24(2):182-187.
13.
EusebiVDamianiSEllisIOAzzopardiJGRosaiJ. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 5 cases. Am J Surg Pathol.2003;27(8):1114-1118.
14.
SagliettiCSchneiderVBongiovanniM, et al. Acinar cell carcinoma of the pancreas with thyroid-like follicular features: first description of a new diagnostic challenging subtype. Virchows Arch.2019;475(6):789-794.
15.
AminMBGuptaROndrejH, et al. Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol.2009;33(3):393-400.
16.
EndoIGonenMYoppAC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg.2008;248(1):84-96.
17.
KonstantinidisITKoerkampBGDoRKG, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758-765.
18.
ParkJKimMHKimKP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver.2009;3(4):298-305.
19.
ValleJWasanHPalmerDH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med.2010;362(14):1273-1281.
20.
de JongMCNathanHSotiropoulosGC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol.2011;29(23):3140-3145.
21.
AkitaMFujikuraKAjikiT, et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol.2017;30(7):986-997.
22.
GuptaADixonE. Epidemiology and risk factors: intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr.2017;6(2):101-104.
23.
SuzukiYMoriTYokoyamaM, et al. Hepatolithiasis: analysis of Japanese nationwide surveys over a period of 40 years. J Hepatobiliary Pancreat Sci.2014;21(9):617-622.
24.
WeinbergBAXiuJLindbergMR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol.2019;10(4):652-662.
25.
LoweryMAPtashkinRJordanE, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res.2018;24(17):4154-4161.
26.
LiauJYTsaiJHYuanRHChangCNLeeHJJengYM. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol.2014;27(8):1163-1173.
27.
FerroneCRTingDTShahidM, et al. The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA in situ hybridization technology. Ann Surg Oncol.2016;23(1):290-296.
28.
ShahidMMubeenATseJ, et al. Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms. Am J Surg Pathol.2015;39(1):25-34.
29.
SigelCSDrillEZhouY, et al. Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns. Am J Surg Pathol.2018;42(10):1334-1345.
30.
IbrahimMEAbadeerKZhaiQJNassarA. Primary hepatic neuroendocrine tumor with unusual thyroid follicular-like morphologic characteristics. Case Rep Pathol.2017;2017:7931975.
31.
EbleJNDelahuntB. Emerging entities in renal cell neoplasia: thyroid-like follicular renal cell carcinoma and multifocal oncocytoma-like tumours associated with oncocytosis. Pathology. 2018;50(1):24-36.
32.
FanelliGNFassanMDal MoroF, et al. Thyroid-like follicular carcinoma of the kidney: the mutational profiling reveals a BRAF wild type status. Pathol Res Pract.2019;215(9):152532.
33.
SiaDLosicBMoeiniA, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun.2015;6:6087.
34.
GrahamRPBarr FritcherEGPestovaE, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol.2014;45(8):1630-1638.
35.
AraiYTotokiYHosodaF, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427-1434.
36.
NogovaLSequistL v.GarciaJMP, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1–3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol.2017;35(2):157-165.
37.
JavleMMShroffRTZhuA, et al. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. J Clin Oncol.2016;34(4):suppl.335.
38.
TaberneroJBahledaRDienstmannR, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol.2015;33(30):3401-3408.
39.
BoradMJChampionMDEganJB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet.2014;10(2):31004135.
40.
KippBRVossJSKerrSE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol.2012;43(10):1552-1558.
41.
BorgerDRTanabeKKFanKC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist.2012;17(1):72-79.
42.
JiaoYPawlikTMAndersRA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet.2013;45(12):1470-1473.
43.
ChriviaJCKwokRPLambN, et al. Phosphoyrlated CREB binds specifically to the nuclear protein CBP. Nature1993;365(6449):855-859.
44.
RaoRCDouY. Hijacked in cancer: the MLL/KMT2A family of methyltransferases. Nat Rev Cancer2015;15(6):334-346.
45.
HellwigMMerkDJLutzB, et al. Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation. Cancer Gene Ther.2020;27(5):294-300.
